Online Testing for Cancer via Liquid Biopsy

The Liquid Biopsy ONLINE webinar series, taking place over three consecutive Tuesdays in November, promises to delve into the latest developments and ongoing challenges in the clinical use of liquid biopsies for precision oncology.

Webinar 1: Leveraging Liquid Biopsy for a More Personalised Approach to Cancer Treatment and Monitoring

Taking place on 14 November at 3pm GMT / 4pm CET / 10am EST, the first webinar will feature talks on evaluating the use of circulating tumour DNA (ctDNA) to guide chemotherapy treatment decisions for colorectal cancer patients and clinical development of liquid biopsy-based assays for children with solid tumors.

Webinar 2: Monitoring MRD in Colorectal Cancer to Advance Precision Medicine

On 21 November at 3pm GMT / 4pm CET / 10am EST, the second webinar will focus on the latest developments in detecting Minimal Residual Disease (MRD) using liquid biopsies in various cancer types. Notable speakers include Pashtoon Kasi, Sara Lonardi, and David Kurtz.

Webinar 3: Overcoming Challenges and Establishing the Clinical Utility of Liquid Biopsies

The final webinar on 28 November at 3pm GMT / 4pm CET / 10am EST will address the clinical considerations that need to be addressed as we enter the prime time for clinical use of liquid biopsies. The webinar will feature talks on the use of liquid biopsies in therapy monitoring, treatment selection, and MRD detection from the latest clinical studies.

Each webinar will provide insights from experts in the field on applications, challenges, and benefits of liquid biopsies in precision oncology. Highlights include the use of advanced biomarkers beyond ctDNA, the integration of AI to improve detection accuracy, and the clinical utility in treatment monitoring.

However, challenges related to data complexity and standardization, regulatory approval, cost-effectiveness, and ethical AI remain active areas of research and discussion.

Registration for one webinar in the series grants access to all subsequent webinars in the series. The event is a 3-part webinar series called "Liquid Biopsy ONLINE."

Attendees will see how the latest methods and innovations are improving the sensitivity, reliability, and clinical utility of liquid biopsies. They will also learn about the latest liquid biopsy assays being developed for various biomarkers and tumor types.

The first talk in the third webinar, "Injectable Priming Agents and Sequencing Technology Innovations to Improve Liquid Biopsy Testing," will be presented by Viktor Adalsteinsson, Director of the Gerstner Center for Cancer Diagnostics and Lead of the Liquid Biopsy Team at the Broad Institute. The second talk in the third webinar, "Clinical Considerations for the Implementation of Liquid Biopsy Testing in Lung Cancer Patients," will be delivered by Paul Hofman, Professor-Clinician and Team Leader at Nice Sophia Antipolis University. The third talk in the third webinar, "Plasma-first" Approach for Molecular Genotyping in Non-small Cell Lung Cancer: opportunities and challenges," will be given by Miguel García-Pardo, Medical Oncologist at Hospital Universitario Ramón y Cajal, Madrid.

The latest developments in the clinical use of liquid biopsies for precision oncology, as discussed in recent expert sources, highlight several key advances and ongoing challenges. Multi-cancer early detection tests can detect signals from several cancer types through a single blood draw, facilitating earlier, more comprehensive screening. Enhanced detection methods such as digital PCR have increased sensitivity and specificity, even for low-abundance biomarkers.

However, the complexity of multi-omics data and biomarker variability requires sophisticated computational tools and standardization across laboratories to ensure reproducibility and clinical validity. Despite technological advances, extensive clinical validation and regulatory approvals remain barriers before widespread clinical adoption of some liquid biopsy applications.

Questions about the optimal frequency of monitoring, cost-benefit balance, and whether earlier detection translates into improved overall survival are still being addressed in ongoing trials. Addressing biases in AI models and implementing ethical frameworks are critical to ensuring equitable precision oncology applications.

In summary, the clinical use of liquid biopsies in precision oncology is rapidly evolving, with advances in AI enabling earlier, more personalized cancer detection and treatment monitoring. The Liquid Biopsy ONLINE webinar series promises to provide valuable insights into this exciting field.

The first webinar, taking place on 14 November, will focus on using circulating tumour DNA (ctDNA) in chemotherapy treatment decisions for colorectal cancer patients, as well as the clinical development of liquid biopsy-based assays for children with solid tumors.
The second webinar on 21 November will delve into the latest developments in detecting Minimal Residual Disease (MRD) using liquid biopsies in various cancer types, featuring notable speakers such as Pashtoon Kasi, Sara Lonardi, and David Kurtz.
The third and final webinar on 28 November will address clinical considerations for the use of liquid biopsies in therapy monitoring, treatment selection, and MRD detection, featuring speakers like Viktor Adalsteinsson, Paul Hofman, and Miguel García-Pardo.
Registration for one webinar grants access to all subsequent webinars in the "Liquid Biopsy ONLINE" series, which runs over three consecutive Tuesdays in November.
Participants will gain insights into the applications, challenges, and benefits of liquid biopsies in precision oncology, including the use of advanced biomarkers beyond ctDNA and the integration of AI to improve detection accuracy.
Ongoing research and discussion are focusing on data complexity and standardization, regulatory approval, cost-effectiveness, the optimal frequency of monitoring, cost-benefit balance, biases in AI models, and implementing ethical frameworks for precision oncology applications.
The latest technological advances in liquid biopsy testing, such as digital PCR and the "Plasma-first" approach, are improving the sensitivity, reliability, and clinical utility of these tests for various biomarkers and tumor types in health-and-wellness and medical-conditions like cancer.